



ABN 53 075 582 740

ASX ANNOUNCEMENT

26 August 2020

Results of General Meeting

Bionomics Limited (ASX:BNO, OTCQB: BNOEF) hereby gives notice to the Australian Securities Exchange ("ASX") that shareholders of the company passed all seven resolutions considered before the General Meeting today.

The Notice of Meeting and accompanying documents were lodged with ASX on 24 August 2020.

This notice is given in accordance with ASX Listing rule 3.13.2 and section 251AA of the Corporations Act 2001.

Resolution Number	Resolutions	Proxy Votes			
		For	Against	Abstain	Proxy's discretion
1	Ratification of the prior issue of 81,500,000 Shares under First Placement	183,734,778 97.41%	3,630,484 1.92%	82,261,547	1,253,168 0.67%
2	Approval for the issue of 54,333,000 Shares under Second Placement	183,520,291 97.35%	3,738,721 1.98%	82,367,797	1,253,168 0.67%
3	Approval for the acquisition of a Relevant Interest by Apeiron and Christian Angermayer of up to 52%	182,785,273 96.95%	4,434,384 2.35%	82,345,379	1,314,941 0.70%
4	Approval for the issue of up to 250,000,000 Shares under further offer underwriting arrangements	183,084,493 97.06%	4,291,075 2.27%	82,251,241	1,253,168 0.67%
5	Confirm appointment of Director – Mr Aaron Weaver	265,235,629 98.25%	3,443,849 1.28%	942,331	1,258,168 0.47%
6	Fees to Non-Executive Directors	253,393,989 97.80%	4,463,255 1.72%	11,769,565	1,235,525 0.48%
7	Approval of proposed issue of Options to Dr Errol De Souza	263,914,977 97.98%	4,154,505 1.54%	1,492,327	1,300,525 0.48%

		Poll Results			Resolution Result
Resolution Number	Resolutions	For	Against	Abstain*	
1	Ratification of the prior issue of 81,500,000 Shares under First Placement	186,111,974 98.09%	3,630,484 1.91%	82,261,547	Carried
2	Approval for the issue of 54,333,000 Shares under Second Placement	185,897,487 98.03%	3,738,721 1.97%	82,367,797	Carried
3	Approval for the acquisition of a Relevant Interest by Apeiron and Christian Angermayer of up to 52%	184,649,342 97.36%	5,009,284 2.64%	82,345,379	Carried
4	Approval for the issue of up to 250,000,000 Shares under further offer underwriting arrangements	184,886,789 97.44%	4,865,975 2.56%	82,251,241	Carried
5	Confirm appointment of Director – Mr Aaron Weaver	267,617,825 98.73%	3,443,849 1.27%	942,331	Carried
6	Fees to Non-Executive Directors	255,640,740 98.28%	4,483,523 1.72%	11,869,565	Carried
7	Approval of proposed issue of Options to Dr Errol De Souza	266,226,728 98.46%	4,174,773 1.54%	1,592,327	Carried

**Not counted in calculating the required majority on a Poll.*

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited

Mr Jack Moschakis

Legal Counsel & Company Secretary

+61 8 8354 6181

jmoschakis@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) and a pipeline of pre-clinical ion channel programs targeting pain, depression, cognition and epilepsy.

www.bionomics.com.au